Based on the SURMOUNT Phase 2 clinical trial. Enter your current weight, target dose, and duration to project your weight loss trajectory — conservative through optimistic.
Conservative
-9.6%
body weight
198.9 lbs
projected weight
-21.1 lbs lost
Typical
-13.7%
body weight
189.9 lbs
projected weight
-30.1 lbs lost
Optimistic
-17.8%
body weight
180.9 lbs
projected weight
-39.1 lbs lost
Projected outcome range at 24 weeks
| Week | % Lost | Weight Lost (lbs) | Projected (lbs) |
|---|---|---|---|
| Week 12 | -8.0% | 17.6 | 202.4 |
| Week 24 | -13.7% | 30.1 | 189.9 |
What -13.7% body weight means for your aesthetics
Facial Aesthetics & Jawline Definition
Significant facial fat reduction at -20%+ body weight reveals underlying bone structure. Cheekbones become prominent, the jawline sharpens, and submental fat (under the chin) is dramatically reduced. Studies show the face reflects weight loss disproportionately — often more than the rest of the body.
Body Recomposition
Retatrutide's GIP + GLP-1 + glucagon triple mechanism produces superior fat oxidation vs dual agonists. Users report preferential loss of visceral and subcutaneous fat, with better lean mass preservation — particularly relevant for physique optimization.
Visceral Fat & Metabolic Shifts
Visceral fat (abdominal cavity fat surrounding organs) is metabolically active and aesthetically impactful. At -22.8% mean weight loss in Phase 2, retatrutide users showed marked abdominal definition improvements. Visceral fat reduction also cuts baseline inflammation — which directly affects skin quality.
Hormonal & Skin Quality Benefits
Obesity-driven hormonal disruption (elevated estrogen, lower testosterone, insulin resistance) reverses substantially at -20%+ weight loss. This translates to improved skin texture, reduced water retention puffiness, and better overall facial symmetry ratios.
Clinical Trial Reference
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
Data reflects 48-week mean percent weight loss from baseline by dose group (4mg, 8mg, 12mg). Trajectory checkpoints are approximated from published Kaplan-Meier curves. Individual results vary.
Research Purposes Only
This calculator is for educational and informational purposes only. Projections are based on mean results from a Phase 2 clinical trial and do not constitute medical advice. Individual results vary significantly. Retatrutide is not FDA-approved for human use. Consult a qualified healthcare provider before beginning any peptide protocol.